Read by QxMD icon Read

Gynecologic Oncology

Sumer Wallace, Kristine T Hanson, Sean C Dowdy, Elizabeth B Habermann
OBJECTIVE: We sought to compare the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey responses of women who underwent gynecologic surgery at our institution across patient factors and surgical approach. METHODS: We identified patients with returned HCAHPS surveys following an inpatient laparoscopic surgery or laparotomy in gynecologic surgery from 10/1/2012-9/30/2015. Exclusions included patient age<18years, discharge by a service other than Gynecologic Surgery, or refusal of Minnesota research authorization...
December 5, 2017: Gynecologic Oncology
Deborah Smith, Colin J R Stewart, Edward M Clarke, Felicity Lose, Claire Davies, Jane Armes, Andreas Obermair, Donal Brennan, Penelope M Webb, Christina M Nagle, Amanda B Spurdle
OBJECTIVE: To measure association between endometrial carcinoma ER and PR status and endometrial cancer (EC) survival, accounting for inter-observer variation. METHODS: The intensity and proportion of tumor cell expression of ER and PR in ECs were assessed independently and semi-quantitatively by two pathologists using digital images of duplicate tumor tissue microarrays (TMAs). Cases with inconsistent initial assessment were reviewed and final scoring agreed. The association between overall and EC-specific survival and hormone receptor expression (intensity, proportion and combined) was assessed using Cox regression analysis...
December 4, 2017: Gynecologic Oncology
Michael J Worley, Kevin M Elias, Neil S Horowitz, Bradley J Quade, Ross S Berkowitz
A 36-year-old with metastatic and refractory choriocarcinoma following single- and multi-agent chemotherapy and surgical metastectomy experienced a durable remission after receiving therapy with an anti-endoglin monoclonal antibody and bevacizumab. Treatment options and scientific advances in this disease are highlighted.
December 4, 2017: Gynecologic Oncology
Christina M Annunziata, Elise C Kohn
The Gynecologic Oncology Group has historically performed ground-breaking, practice-changing clinical trials in women's cancers. The current standard of care for initial treatment of ovarian, endometrial, cervical, and trophoblastic cancers was determined by clinical trials completed within this cooperative group structure. For example, trial GOG-0111 set the standard for combining platinum and taxane chemotherapy in ovarian cancer, and more recently GOG-0240 provided evidence for adding bevacizumab to chemotherapy for women with advanced cervical cancer...
December 3, 2017: Gynecologic Oncology
Renata R Urban, Hao He, Raphael Alfonso, Melissa M Hardesty, Barbara A Goff
OBJECTIVE: To describe the Medicare payments at the end of life for patients with advanced ovarian cancer, and assess factors responsible for payment variation METHODS: Using the linked Surveillance, Epidemiology and End Results (SEER)-Medicare database, we identified a cohort of women with stage III/IV epithelial ovarian cancer diagnosed between 1995 and 2007. We defined the end of life as the last 90days prior to death. Total medical costs were estimated from overall Medicare payments, and adjusted for geography and for inflation to the 2009 U...
December 3, 2017: Gynecologic Oncology
Anjila Koul, Eva L Forsland, Maria Bjurberg
OBJECTIVE: Aim of this study was observation of hypersensitivity reaction (HSR) frequency by using a 3-hour graduated infusion protocol with appropriate premedication as a prophylactic measure in patients with gynecological cancer receiving carboplatin retreatment in second line or above. None of the patients had experienced HSRs to platinum previously. METHOD: All the patients in this study received premedication with corticosteroids and anti-histamines followed by carboplatin as 3-hour graduated infusion...
December 2, 2017: Gynecologic Oncology
Kuo-Chang Wen, Pi-Lin Sung, Yu-Ting Chou, Chih-Ming Pan, Peng-Hui Wang, Oscar Kuang-Sheng Lee, Cheng-Wen Wu
OBJECTIVE: EpCAM is a transmembrane glycoprotein that functions as an epithelial marker in endometrial tissues. However, the correlation between EpCAM and endometrial carcinoma (EC) is not clear. METHODS: This study investigated the association between EpCAM and EC. Immunohistochemistry staining and bioinformatics analysis disclosed the clinical importance of low EpCAM expression. The migratory ability of cells expressing low EpCAM levels was studied in transwell invasion assays in vitro and an orthotopic intra-uterine tumor injection model in vivo...
December 2, 2017: Gynecologic Oncology
Paulina Cybulska, Cheryl Goss, William P Tew, Rekha Parameswaran, Yukio Sonoda
No abstract text is available yet for this article.
December 1, 2017: Gynecologic Oncology
Umesh Mahantshetty, Tanuja Teni, Pushpa Naga, Chandni Hotwani, Sumuki Umesh, Sadhana Kannan, Vinod Hande, Sagar Pawar, Reena Engineer, Supriya Chopra, Kedar Deodhar, Amita Maheshwari, Lavanya Gurram, Sudeep Gupta, Shyam Kishore Shrivastava
OBJECTIVE: With an aim to investigate the impact of Human Papilloma Virus (HPV) 16/18 infection on clinical outcomes in locally advanced cervical cancers treated with radical radio (chemo) therapy, we undertook this prospective study. METHODS: Between May 2010 and April 2012, 150 histologically proven cervical cancer patients treated with radio (chemo) therapy were accrued. Cervical biopsies/brushings were collected at pre-treatment, end of treatment and at 3 monthly intervals up to 24months...
December 1, 2017: Gynecologic Oncology
Jun Li, Shufen Li, Hinlin Yu, Jieyu Wang, Congjian Xu, Xin Lu
OBJECTIVE: There is no consensus regarding what should be the optimal single-agent regimen in low-risk gestational trophoblastic neoplasia(LRGTN). we performed this network meta-analysis(NMA) and our aim is to synthesize all efficacy evidence, enabling a comparison of all single-agent methotrexate(MTX)-based or actinomycin-d(Act-D)-based regimens in LRGTN. METHODS: We performed a literature search of PubMed, Embase, and the Cochrane Library for all relevant articles...
December 1, 2017: Gynecologic Oncology
C A Hamilton, A Miller, Y Casablanca, N S Horowitz, B Rungruang, T C Krivak, S D Richard, N Rodriguez, M J Birrer, F J Backes, M A Geller, M Quinn, M J Goodheart, D G Mutch, J J Kavanagh, G L Maxwell, M A Bookman
OBJECTIVE: To identify clinicopathologic factors associated with 10-year overall survival in epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC), and to develop a predictive model identifying long-term survivors. METHODS: Demographic, surgical, and clinicopathologic data were abstracted from GOG 182 records. The association between clinical variables and long-term survival (LTS) (>10years) was assessed using multivariable regression analysis. Bootstrap methods were used to develop predictive models from known prognostic clinical factors and predictive accuracy was quantified using optimism-adjusted area under the receiver operating characteristic curve (AUC)...
November 28, 2017: Gynecologic Oncology
Omari K Johnson, Andrew Berchuck, Angeles A Secord, Andrew C Peterson
Urinary diversion has been in the scope of practice of Gynecologic Oncologists since the inception of the sub-specialty. However, many fewer urinary diversions are performed currently than in the past due to improved prevention of cervical cancer. The intent of this article is to provide a state of the art review for Gynecologic Oncologists. Surgeons performing these complex procedures must be knowledgeable about the differences between various types of continent and non-continent urinary diversions, and the principles of pre and post-operative care...
November 28, 2017: Gynecologic Oncology
Junyong Zhu, Zuhua Chen, Lei Yong
The majority of genes are alternatively spliced and growing evidence suggests that alternative splicing is modified in cancer and is associated with cancer progression. Systematic analysis of alternative splicing signature in ovarian cancer is lacking and greatly needed. We profiled genome-wide alternative splicing events in 408 ovarian serous cystadenocarcinoma (OV) patients in TCGA. Seven types of alternative splicing events were curated and prognostic analyses were performed with predictive models and splicing network built for OV patients...
November 27, 2017: Gynecologic Oncology
Woo Dae Kang, U Chul Ju, Seok Mo Kim
OBJECTIVES: Our aim was to estimate the risk of disease incidence in women with atypical squamous cell of undetermined significance (ASC-US) without histology-proven cervical intraepithelial neoplasia grade 2 or worse (CIN2+) by human papillomavirus (HPV) genotype. METHODS: Between January 2002 and September 2010, incidence of CIN2+ in 2880 women including 2172 with ASC-US and histology-proven negative and 708 with ASC-US with histology-proven CIN1 was investigated...
November 25, 2017: Gynecologic Oncology
Sarah J Kitson, Jennifer Lindsay, Vanitha N Sivalingam, Mark Lunt, Neil A J Ryan, Richard J Edmondson, Martin K Rutter, Emma J Crosbie
BACKGROUND: Cardiovascular disease is a major cause of death in endometrial cancer survivors. The aim of this study was to determine whether women newly diagnosed with endometrial cancer have a higher prevalence of cardiovascular risk factors than the general population. METHODS: The prevalence of adequately treated and unrecognized/inadequately treated cardiovascular risk factors and the corresponding 10-year cardiovascular risk by QRISK2 score was measured in 150 consecutive women undergoing primary treatment for endometrioid endometrial cancer in the North West of England, and 746 age and ethnicity-matched control women from the Health Survey for England 2014...
November 24, 2017: Gynecologic Oncology
Rajmohan Murali, Rachel N Grisham, Robert A Soslow
The role of the pathologist in the multidisciplinary management of women with gynecologic cancer has evolved substantially over the past decade. Pathologists' evaluation of parameters such as pathologic stage, histologic subtype, grade and microsatellite instability, and their identification of patients at risk for Lynch syndrome have become essential components of diagnosis, prognostic assessment and determination of optimal treatment of affected women. Despite the use of multimodality treatment and combination cytotoxic chemotherapy, the prognosis of women with advanced-stage gynecologic cancer is often poor...
November 23, 2017: Gynecologic Oncology
Haley A Moss, Laura J Havrilesky
Patient-reported outcomes (PRO) are defined as a report of a patient's symptoms, function and general well-being that comes directly from the patient, without interpretation of the response by a medical provider. As greater emphasis is placed on high-quality, patient-centered care, the importance of PROs has become widely accepted by policymakers, third party payers, medical societies, health care systems and clinical researchers. Despite increased recognition of the importance of PROs, they have not become a widely-implemented part of clinical care and their use in clinical research has been limited by methodological concerns...
November 23, 2017: Gynecologic Oncology
Sonia Guleria, Allan Jensen, Susanne K Kjær
OBJECTIVE: A growing number of studies suggest that some ovarian cancers can arise from benign and borderline ovarian tumors. However, studies on the association between benign and borderline ovarian tumors are lacking. We studied the overall- and histotype-specific risk of borderline ovarian tumors among women with a benign ovarian tumor. METHODS: This nationwide cohort study included all Danish women diagnosed with a benign ovarian tumor (n=139,466) during 1978-2012...
November 23, 2017: Gynecologic Oncology
Neil S Horowitz, G Larry Maxwell, Austin Miller, Chad A Hamilton, Bunja Rungruang, Noah Rodriguez, Scott D Richard, Thomas C Krivak, Jeffrey M Fowler, David G Mutch, Linda Van Le, Roger B Lee, Peter Argenta, David Bender, Krishnansu S Tewari, David Gershenson, James J Java, Michael A Bookman
OBJECTIVE: Microscopic residual disease following complete cytoreduction (R0) is associated with a significant survival benefit for patients with advanced epithelial ovarian cancer (EOC). Our objective was to develop a prediction model for R0 to support surgeons in their clinical care decisions. METHODS: Demographic, pathologic, surgical, and CA125 data were collected from GOG 182 records. Patients enrolled prior to September 1, 2003 were used for the training model while those enrolled after constituted the validation data set...
November 22, 2017: Gynecologic Oncology
Yong Jae Lee, Young Shin Chung, Jung-Yun Lee, Eun Ji Nam, Sang Wun Kim, Sunghoon Kim, Young Tae Kim
OBJECTIVE: To investigate the relationship of the time interval from the completion of neoadjuvant chemotherapy (NAC) to the initiation of postoperative adjuvant chemotherapy (POAC) with the survival outcomes in patients with ovarian cancer. METHODS: We retrospectively investigated 220 patients with pathologically confirmed epithelial ovarian cancer who received NAC at Yonsei Cancer Hospital between 2006 and 2016. The time interval was defined as the period from the completion of NAC, spanning interval debulking surgery (IDS), to the initiation of POAC...
November 21, 2017: Gynecologic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"